European listed biotech landscape: 2019 review and outlook for 2020

2018 was a very bad year for the European biotech landscape, so the question was whether a rebound could take place or not in 2019, in a global environment where the recurring macro themes basically remained unchanged: US/China trade war, Brexit, rates, recession fears (you know, the one that is announced every year for the[…]